Advance of novel target strategies participating in myocardial ischemia reperfusion injury

HOU Kai; TAN Haoyu; LIU Jing; LI Yunman

doi:10.11665/j.issn.1000-5048.20220205

Journal of China Pharmaceutical University > 2022 > 53(2): 164-170. > DOI: 10.11665/j.issn.1000-5048.20220205

HOU Kai, TAN Haoyu, LIU Jing, LI Yunman. Advance of novel target strategies participating in myocardial ischemia reperfusion injury[J]. Journal of China Pharmaceutical University, 2022, 53(2): 164-170. DOI: 10.11665/j.issn.1000-5048.20220205

Citation:

PDF (813 KB)

Advance of novel target strategies participating in myocardial ischemia reperfusion injury

1.
Department of Pharmacy, Zhongda Hospital, Southeast University, Nanjing 210009
2.
Cardiovascular Surgery, The Second XiangYa Hospital of Central South University, Changsha 410000
3.
State Key Laboratory of Natural Medicines, Department of Physiology, China Pharmaceutical University, Nanjing 210009, China

Funds: This project was supported by China Pharmaceutical University "Double First-Class" Construction Technology Innovation Team Project (No.CPU2018GY23)

More Information

Received Date: October 27, 2021
Revised Date: February 27, 2022

Graphical Abstract

Abstract

Abstract

Worldwide morbidity and mortality of acute myocardial infarction (AMI) and related heart failure are still high.While effective early reperfusion of the criminal coronary artery after a confirmed AMI is the typical and effective treatment at present, collateral myocardial ischemia reperfusion injury (MIRI) and pertinent cardio-protection are still challenging to address and have inadequately understood mechanisms.One important reason might be that AMI is multifactorial, causing cardiomyocyte death via multiple mechanisms, as well as affecting other cell types, including platelets, fibroblasts, endothelial and smooth muscle cells, and immune cells.Many cardioprotective strategies act through common end-effectors and may be suboptimal in patients with comorbidities.Therefore, unveiling the related multitarget strategies participating in triggering and resisting the pathobiology of MIRI is a promising and valuable frontier.The review specifically focuses on the recent MIRI advances that are supported by multitarget strategies and new targets under development in order to bring the rational combination of multitarget therapies up to date, as well as to identify findings that may facilitate the new drug of novel targets.
- myocardial ischemia,
- ischemia-reperfusion injury,
- multiple targets,
- cardioprotective strategies,
- novel targets,
- advances

FullText(HTML)

References (38)

References

[1]	. Exp Ther Med，2015，9（2）：603-611.
[2]	Hou K，Li YM. Developments on novel molecular targets participating in myocardial ischemia reperfusion injury［J］. Med Res Educ（医学研究与教育），2020，37（3）：1-9.
[3]	Heusch G. Myocardial ischaemia-reperfusion injury and cardioprotection in perspective［J］. Nat Rev Cardiol，2020，17（12）：773-789.
[4]	Hausenloy DJ，Botker HE，Engstrom T，et al. Targeting reperfusion injury in patients with ST-segment elevation myocardial infarction：trials and tribulations［J］.Eur Heart J，2017，38（13）：935-941.
[5]	Heusch G，Gersh BJ. The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion：a continual challenge［J］.Eur Heart J，2017，38（11）：774-784.
[6]	Hausenloy DJ，Garcia-Dorado D，B?tker HE，et al. Novel targets and future strategies for acute cardioprotection：position paper of the european society of cardiology working group on cellular biology of the heart［J］.Cardiovasc Res，2017，113（6）：564-585.
[7]	Inserte J，Hernando V，Vilardosa ú，et al. Activation of cGMP/protein kinase G pathway in postconditioned myocardium depends on reduced oxidative stress and preserved endothelial nitric oxide synthase coupling［J］.J Am Heart Assoc，2013，2（1）：e005975.
[8]	Szabó MR，Pipicz M，Csont T，et al. Modulatory effect of myokines on reactive oxygen species in ischemia/reperfusion［J］.Int J Mol Sci，2020，21（24）：9382.
[9]	Kleinbongard P，Amanakis G，Skyschally A，et al. Reflection of cardioprotection by remote ischemic perconditioning in attenuated ST-segment elevation during ongoing coronary occlusion in pigs：evidence for cardioprotection from ischemic injury［J］ Circ Res，2018，122（8）：1102-1108.
[10]	Figueras J，Otaegui I，Marti G，et al. Area at risk and collateral circulation in a first acute myocardial infarction with occluded culprit artery. STEMI vs non-STEMI patients［J］. Int J Cardiol，2018，259：14-19.
[11]	Ibanez B，James S，Agewall S，et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation：the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology （ESC）［J］.Eur Heart J，2018，39（2）：119-177.
[12]	Abrial M，da Silva CC，Pillot B，et al. Cardiac fibroblasts protect cardiomyocytes against lethal ischemia-reperfusion injury［J］.J Mol Cell Cardiol，2014，68：56-65.
[13]	Hausenloy DJ，Chilian W，Crea F，et al. The coronary circulation in acute myocardial ischaemia/reperfusion injury：a target for cardioprotection［J］.Cardiovasc Res，2019，115（7）：1143-1155.
[14]	Schanze N，Bode C，Duerschmied D. Platelet contributions to myocardial ischemia/reperfusion injury［J］.Front Immunol，2019，10：1260.
[15]	Fernández-Jiménez R，Barreiro-Pérez M，Martin-García A，et al. Dynamic edematous response of the human heart to myocardial infarction：implications for assessing myocardial area at risk and salvage［J］.Circulation，2017，136（14）：1288-1300.
[16]	Schwiebert C，Huhn R，Heinen A，et al. Postconditioning by xenon and hypothermia in the rat heart in vivo［J］.Eur J Anaesthesiol，2010，27（8）：734-739.
[17]	Alburquerque-Béjar JJ，Barba I，Inserte J，et al. Combination therapy with remote ischaemic conditioning and insulin or exenatide enhances infarct size limitation in pigs［J］.Cardiovasc Res，2015，107（2）：246-254.
[18]	Sun JH，Aponte AM，Menazza S，et al. Additive cardioprotection by pharmacological postconditioning with hydrogen sulfide and nitric oxide donors in mouse heart：S-sulfhydration vs. S-nitrosylation［J］.Cardiovasc Res，2016，110（1）：96-106.
[19]	Alexopoulos P，Panoutsopoulou K，Vogiatzis G，et al. Combined treatment with exenatide and cyclosporine A or parstatin 1-26 results in enhanced reduction of infarct size in a rabbit model［J］.J Cardiovasc Pharmacol，2017，70（1）：34-41.
[20]	Koshinuma S，Miyamae M，Kaneda K，et al. Combination of necroptosis and apoptosis inhibition enhances cardioprotection against myocardial ischemia-reperfusion injury［J］.J Anesth，2014，28（2）：235-241.
[21]	Audia JP，Yang XM，Crockett ES，et al. Caspase-1 inhibition by VX-765 administered at reperfusion in P2Y 12 receptor antagonist-treated rats provides long-term reduction in myocardial infarct size and preservation of ventricular function［J］.Basic Res Cardiol，2018，113（5）：32.
[22]	Aryal B，Price NL，Suarez Y，et al. ANGPTL4 in metabolic and cardiovascular disease［J］. Trends Mol Med，2019，25（8）：723-734.
[23]	Lux A，Pokreisz P，Swinnen M，et al. Concomitant phosphodiesterase 5 inhibition enhances myocardial protection by inhaled nitric oxide in ischemia-reperfusion injury［J］.J Pharmacol Exp Ther，2016，356（2）：284-292.
[24]	Yang XM，Cui L，White J，et al. Mitochondrially targeted Endonuclease III has a powerful anti-infarct effect in an in vivo rat model of myocardial ischemia/reperfusion［J］.Basic Res Cardiol，2015，110（2）：3.
[25]	Xin P，Zhu W，Li J，et al. Combined local ischemic postconditioning and remote perconditioning recapitulate cardioprotective effects of local ischemic preconditioning［J］.Am J Physiol Heart Circ Physiol，2010，298（6）：H1819-H1831.
[26]	Huang MH，Wu YW，Nguyen V，et al. Heart protection by combination therapy with esmolol and milrinone at late-ischemia and early reperfusion［J］.Cardiovasc Drugs Ther，2011，25（3）：223-232.
[27]	Fan Y，Yang SS，Zhang XK，et al. Comparison of cardioprotective efficacy resulting from a combination of atorvastatin and ischaemic post-conditioning in diabetic and non-diabetic rats［J］. Clin Exp Pharmacol Physiol，2012，39（11）：938-943.
[28]	Tratsiakovich Y，Gonon AT，Kiss A，et al. Myocardial protection by co-administration of L-arginine and tetrahydrobiopterin during ischemia and reperfusion［J］.Int J Cardiol，2013，169（1）：83-88.
[29]	Wang Q，Liu GP，Xue FS，et al. Combined vagal stimulation and limb remote ischemic perconditioning enhances cardioprotection via an anti-inflammatory pathway［J］.Inflammation，2015，38（5）：1748-1760.
[30]	Eitel I，Stiermaier T，Rommel KP，et al. Cardioprotection by combined intrahospital remote ischaemic perconditioning and postconditioning in ST-elevation myocardial infarction：the randomized LIPSIA CONDITIONING trial［J］.Eur Heart J，2015，36（44）：3049-3057.
[31]	Pasupathy S，Tavella R，Grover S，et al. Early use of N-acetylcysteine with nitrate therapy in patients undergoing primary percutaneous coronary intervention for ST-segment-elevation myocardial infarction reduces myocardial infarct size （the NACIAM trial［N-acetylcysteine in acute myocardial infarction］）［J］.Circulation，2017，136（10）：894-903.
[32]	Rout A，Sukhi A，Chaudhary R，et al. Investigational drugs in phase II clinical trials for acute coronary syndromes［J］.Expert Opin Investig Drugs，2020，29（1）：33-47.
[33]	Ziegler M，Haigh K，Nguyen T，et al. The pulmonary microvasculature entraps induced vascular progenitor cells （iVPCs） systemically delivered after cardiac ischemia-reperfusion injury：indication for preservation of heart function via paracrine effects beyond engraftment［J］. Microcirculation，2019，26（2）：e12493.
[34]	Audia JP，Yang XM，Crockett ES，et al. Caspase-1 inhibition by VX-765 administered at reperfusion in P2Y 12 receptor antagonist-treated rats provides long-term reduction in myocardial infarct size and preservation of ventricular function［J］.Basic Res Cardiol，2018，113（5）：32.
[35]	Rossello X，Yellon DM. The RISK pathway and beyond［J］. Basic Res Cardiol，2017，113（1）：1-5.
[36]	Yang XL，Yue RC，Zhang J，et al. Gastrin protects against myocardial ischemia/reperfusion injury via activation of RISK （reperfusion injury salvage kinase） and SAFE （survivor activating factor enhancement） pathways［J］.J Am Heart Assoc，2018，7（14）：e005171.
[37]	Olshan DS，Rader DJ. Angiopoietin-like protein 4：a therapeutic target for triglycerides and coronary disease［J］？J Clin Lipidol，2018，12（3）：583-587.
[38]	Gibson CM，Giugliano RP，Kloner RA，et al. EMBRACE STEMI study：a Phase 2a trial to evaluate the safety，tolerability，and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention［J］.Eur Heart J，2016，37（16）：1296-1303.

Cited By

Cited by

Periodical cited type(12)

1.	熊坚，黄小刚，赵惠芳，凌发样，郑倩华，王姿雯，齐文川，梁繁荣. 针灸治疗心肌缺血再灌注损伤研究现状与热点分析. 世界科学技术-中医药现代化. 2025(01): 179-194 .
2.	门汝梅，王艳林，张琳娜，门丽丽，兰文达，孟庆兰，于建才. 美托洛尔联合氯吡格雷对心肌缺血再灌注损伤小鼠的作用机制. 西部医学. 2024(03): 365-371 .
3.	山文菊，崔君，蹇玉红，封林奇，易蔚，孙阳. 衣康酸在心肌缺血再灌注损伤中的动态变化及其作用研究. 中国体外循环杂志. 2024(02): 139-144 .
4.	贾凌梅，陈亚丽，贾敏，刘畅，栾莹莹，张颖. 参松养心胶囊通过铁死亡途径保护心肌缺血再灌注损伤研究. 现代中西医结合杂志. 2024(08): 1072-1076 .
5.	李萍，洪薇，雷晓燕，闫莉. 急诊护理分级责任制整体服务对急性心肌梗死患者的抢救效果. 名医. 2024(04): 132-134 .
6.	魏琴，陈冰心，赵翎，阿曼古丽·如则，赵帮豪，姜涛，张春，李志强，段明军，高晓明. 松弛素抑制氧化应激反应保护小鼠心肌微血管内皮细胞的缺氧/复氧损伤. 中国组织工程研究. 2023(23): 3621-3627 .
7.	郑祥，王审. 自拟活血舒痹汤治疗急性心肌梗死PCI术后缺血再灌注损伤的临床研究. 中华全科医学. 2023(06): 966-969+972 .
8.	毛雨，沈童童，费亮，王健，陈良余. CHA2DS2-VASc评分、血清肌酐对急性ST段抬高型心肌梗死介入术后发生院内不良事件的预测价值. 山东医药. 2023(22): 61-64 .
9.	吴丛宇，周悦，上官璐茜，杨雅妮，王晶雅，余俊河，宫帅帅，寇俊萍. 大黄素的药理作用机制研究进展. 中国药科大学学报. 2023(05): 634-643 . 本站查看
10.	刘盼，王晓英，韩丹. 地黄苷A通过调节AKT/Nrf2/GPX4信号通路介导的铁死亡改善大鼠心肌缺血再灌注损伤. 中西医结合心脑血管病杂志. 2023(22): 4112-4119 .
11.	王德勇，涂英兵，袁娟，张珏，张禾. 基于PERK/Nrf2/HO-1信号通路研究瑞马唑仑对心肌缺血再灌注损伤大鼠铁死亡的影响. 现代生物医学进展. 2023(23): 4427-4433 .
12.	骆春旭. 迷迭香酸在心血管疾病中的应用研究进展. 生物化工. 2022(04): 151-153+158 .

Other cited types(3)

Get Citation

PDF

XML

Article views (981) PDF downloads (1100) Cited by(15)

Turn off MathJax

Article Contents

Abstract

References

Advance of novel target strategies participating in myocardial ischemia reperfusion injury

Abstract

References

Cited by

Periodical cited type(12)

Other cited types(3)

Catalog

Export File

Citation

Format

Content